Sprycel and Breastfeeding
No research has been done to determine if Sprycel (dasatinib) passes through breast milk. However, based on the properties of the drug, it is thought that Sprycel would pass through breast milk and could cause potentially serious side effects in a nursing infant. Due to these possible risks, the manufacturer of the drug recommends that women not take Sprycel while breastfeeding.
Sprycel® (dasatinib) is a prescription medication used in the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. At this time, it is unknown if this medication passes through human breast milk. If you are breastfeeding or planning to start, talk to your healthcare provider before taking Sprycel.
Sprycel has not been studied in women who are breastfeeding. Therefore, it is unknown if the drug passes through human breast milk, or if it would harm a nursing infant. Based on the properties of the drug, it is expected to pass through breast milk to some extent; however, probably not in large amounts.
Sprycel is associated with potentially serious side effects. Because of the potential for these side effects in a nursing infant, the manufacturer of the medication recommends women either choose to breastfeed or use the drug, but not to do both.
If your healthcare provider recommends breastfeeding while using Sprycel, be watchful for any problems in your child. Contact your child's healthcare provider if you notice any possible Sprycel side effects, including but not limited to:
- Excessive sleeping
- Excessive crying
- Difficulty breathing
- Problems feeding.